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Abstract
Background Huntington disease prevalence was first estimated in Grampian, northern Scotland in 1984. Molecular testing 
has since increased ascertainment.
Objective To estimate the prevalence of manifest Huntington disease and identified pre-symptomatic gene expansion carri-
ers (IPGEC) in northern Scotland, and estimate the magnitude of biases in prevalence studies that rely upon routine coding 
in primary care records.
Methods Cases were ascertained using North of Scotland genetic laboratory, clinic, and hospital records. Prevalence was 
calculated for manifest and IPGEC on 01/07/2016 and 01/01/2020 and compared with local published data.
Results The prevalence of manifest Huntington disease in northern Scotland in 2020 was 14.6 (95% CI 14.3–15.3) per 
100,000, and of IPGEC was 8.3 (95% CI 7.8–9.2) per 100,000. Whilst the population of northern Scotland decreased by 
0.05% between 2016 and 2020, the number of manifest and identified pre-symptomatic gene expansion carriers increased 
by 7.4% and 23.3%, respectively. Manifest disease in Grampian increased by 45.9% between 1984 and 2020. More women 
than men had a diagnosis. General Practice coding underestimated symptomatic molecularly confirmed prevalence by 2.2 
per 100,000 people.
Conclusion Even in an area with previously high ascertainment, there has been a 45.9% increase in manifest Huntington 
disease over the last 30 years. Within our catchment area, prevalence varies between health board regions with similar com-
munity-based services. Such variation in prevalence could have major drug cost and service delivery implications, especially 
if expensive, complexly administered therapies prove successful. Health services should gather accurate population-based 
data on a regional basis to inform service planning.
Keywords Huntington Disease · Prevalence · Scotland · General practice
Introduction
Huntington disease (HD) is an autosomal dominant adult-
onset neurodegenerative disorder caused by the expansion 
of a glutamine (CAG) repeat tract within exon 1 of the 
Huntington (HTT) gene [1]. Although to date, there is no 
disease-modifying treatment, promising results from a trial 
of anti-sense oligonucleotide (ASO) therapies are offering 
affected families hope [2, 3]. Thus, having an accurate preva-
lence estimate for the population is increasingly important 
for service planning.
The North of Scotland comprises a relatively large geo-
graphic area of the UK, with a rurally distributed population. 
Health services free at the point of delivery are administered 
through two major health board areas (NHS Grampian and 
NHS Highland) and three remote island health boards (NHS 
Shetland, NHS Orkney, and NHS Western Isles). Popula-
tion-based studies of prevalence of genetic disorders in the 
North of Scotland are facilitated by a detailed family-based 
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electronic record system, integration of the genetic labo-
ratory and clinical services, the Scottish electronic patient 
record system, and long-standing, accurate, and accessible 
registration of births, marriages, and deaths.
HD was first reported in northern Scotland in the Black 
Isle region (Highland health board) in 1930 [4]. Careful 
family-based ascertainment by Simpson and Johnston [4] 
led to the first formal publication of the prevalence of HD in 
Grampian in 1989. The health board boundary of Grampian 
has not changed since the study by Simpson and Johnston 
[4]. However, in this study, we report data from a much 
larger geographic area as our clinic now also serves NHS 
Highland and the other island health boards. In 1989, genetic 
testing was conducted using linkage analysis, and diagnosis 
was only confirmed in the presence of characteristic move-
ment disorder with a family history of such. This contrasts 
with the current direct mutation testing method that counts 
the number of CAG repeats in the HTT gene. For many 
years, this prevalence of 9.94 per 100,000 people remained 
amongst the highest recorded, beyond the small population 
of the lake Maracaibo area in Venezuela [5]. Morrison et al. 
[6] also reported a similarly high prevalence of 10.6 per 
100,000 in Northern Ireland. Since the identification of the 
HTT gene in 1993, awareness of HD has increased [7].
Several studies have used general practice (GP) diag-
nostic codes to estimate HD incidence and prevalence in 
research active practices across the UK [8–10]. However, 
there was no molecular confirmation of the study popula-
tions, and observation in our clinic led us to suspect that 
identified pre-symptomatic gene expansion carriers (IPGEC) 
might be miscoded as symptomatic, falsely elevating mani-
fest HD prevalence.
The aim of this study was to update the regional preva-
lence estimates for the purposes of service planning, using 
routine data, and to calculate a correction factor for improv-
ing prevalence estimates based on GP coding.
Materials and methods
Patient inclusion criteria
Any individual who was living in the North of Scotland on 
01/07/2016 and on 01/01/2020 with 36 or more CAG repeats 
in HTT mutation was included. Such individuals were con-
sidered to manifest disease in the presence of characteristic 
movement disorder assessed by an experienced European 
Network of Huntington Disease (EHDN) certified rater.
Sources of ascertainment
Patients were ascertained using NHS Grampian genetic 
department laboratory and clinic records. Prevalence was 
estimated for manifest and identified pre-symptomatic 
gene expansion carriers on 01/07/2016 and on 01/01/2020. 
Population figures were obtained from published local 
council demographic data for 2016 and 2019 [11]. NHS 
patient records were examined to identify the number of 
CAG repeats on the affected allele for manifest and pre-
symptomatic HD, as well as their age and gender. Molecu-
lar testing took place in a single ISO accredited genetics 
laboratory with a special interest in HD. There is only 
one HD clinic in the North of Scotland; all HD patients 
ascertained by the regional laboratory and the local fam-
ily organisation employed community-based nurses, who 
working closely with the clinic are referred. The clinical 
lead of the HD service also leads the genetics laboratory, 
and this fosters joint working and thus supports ascer-
tainment. A very small number of patients resident in the 
region may be unknown to the clinic if they were tested 
in another laboratory south of Grampian but in our expe-
rience this is very uncommon. There may also be some 
affected people in the population who have not come for-
ward for diagnosis.
General practitioner (GP) coding
To assess the accuracy of GP coding, the history section 
of GP referral letters within the hospital electronic patient 
record was examined to estimate: (1) the proportion of 
IPGEC whose GP records were coded “Huntington Dis-
ease”; and (2) the proportion of symptomatic HD patients 
whose GP records were coded "Huntington Disease". A 
retrospective case note review of North of Scotland genetic 
clinic records and Trakcare, the NHS Grampian electronic 
healthcare record was performed. GP coding was exam-
ined by retrospective review of GP referral letters held in 
the available electronic secondary care electronic patient 
records for manifest HD patients and Identified IPGEC.
Statistical analysis
Prevalence was calculated by the following equation: 
[Prevalence (per 100,000 people) = Number of individu-
als/Population × 100000], for manifest HD and IPGEC, for 
each NHS health board and for the North of Scotland in 
total, together with along with binomial 95% confidence 
intervals (CI) based on Poisson distribution assumption, 
where Poisson parameter (λ) was defined as λ = k/n. Total 
events (k) were imputed as the total number of patients 
identified either as manifesting or pre-symptomatic to the 
population (n) of each health board at the examined time.
A paired t test was used to compare the rate of manifest 
and IPGEC individuals between health board areas between 
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2016 and 2020. The false discovery rate was assessed via 
a two-stage linear step-up procedure of Benjamini et al. 
[12]. Bar charts were employed to visualise the prevalence 
amongst the health boards between 2016 and 2020. Simple 
linear regression and non-linear fit (Gaussian) tests were 
employed to compare the pattern and correlation of distri-
butions between NHS Grampian and Highland HD. Signifi-
cance was assessed by paired two-tailed t test analysis. Two-
tailed p values were calculated and visualised according to 
the NJEM scale, with p values < 0.05 being considered as 
the threshold for statistical significance. Historic prevalence 
data for NHS Grampian were obtained from published work; 
the health board boundaries have not changed. Percentage 
change was calculated according to the following formula: 




The molecularly confirmed prevalence of manifest HD in 
northern Scotland in 2020 was 14.6 (95% CI 14.3–15.3) 
per 100,000, and of IPGEC was 8.3 (95% CI 7.8–9.2) per 
100,000. Table 1 shows prevalence by NHS health board. 
In line with Scottish data governance policy, where num-
ber of cases was less than 5 the exact data point was not 
given to protect anonymity. The IPGEC prevalence data 
represent the prevalence of individuals who had genetic 
testing for HD in the population and who were pre-symp-
tomatic at the time of assessment. Highland health board 
had the highest regional prevalence of molecularly con-
firmed symptomatic HD and IPGEC (Table 1), but the 
difference in rate between Grampian and Highland was 
not statistically significant (p = 0.6) (Fig. 1). 
Whilst the population in the North of Scotland 
decreased by 0.05% between 2016 and 2020, the num-
ber of manifest HD patients increased by 7.4%, and the 
number of IPGEC increased by 23.3%. Between 2016 and 
2020, three patients moved out of the study area, and 27 
known gene positive carriers became manifest. All indi-
viduals who had a predictive test and a bad news result 
remained domiciled in the region on the 2020 prevalence 
date.
In Grampian, the number of manifest HD cases increased 
by 11.8%, and the number of IPGEC increased by 17.9%, 
whilst the population in Grampian decreased by 0.4% 
between 2016 and 2020. In contrast within Highland, the 
population increased by 0.7% between 2016 and 2020, and 
the number of pre-symptomatic patients increased by 28.6% 
but there was no increase in the number of manifest patients.
The number of cases in each of the Island health boards 
of Shetland, Orkney and Western Isles was low, and in line 
with NHS Scotland policy, these data are summarised as 
“< 5” for these boards combined.
Table 1  HD prevalence data for regions in the North of Scotland on 01/07/2016 and on 01/01/2020




































Manifest < 5 < 5 71,910 71,940 4.17 (3.0–5.0) 4.17 (3.0–5.0)




< 5 < 5
North of Scot-
land (Total)





< 78 < 65 8.3 (7.8–9.2) 6.7 (6.0–7.4)




The range of CAG repeat lengths in the affected allele was 
examined in Grampian and Highland. The percentage of HD 
population (manifest and IPGEC) from each region for each 
CAG repeat length was calculated (Fig. 2a). The Pearson 
correlation test depicted a positively and statistically signifi-
cant correlation between CAG Grampian and CAG High-
land datasets (Pearson r = 0.8163, p (two-tailed) = < 0.0001). 
Larger CAG repeat tracts were more common in Highland 
compared to Grampian (Grampian median: 42; Highland 
median: 43) (Fig. 2a), whilst the linear regression analysis 
amongst the two populations demonstrated that this differ-
ence was significant (p value: 0.0125) (Fig. 2b).
Age and gender distribution
Age and gender distribution of manifest HD in the North 
of Scotland is shown in Fig. 3a. More women than men 
with manifest HD were ascertained (60.5% vs. 39.5%) on 
01/01/2020. Most female individuals belonged to the 51–60 
age group, whereas most male individuals belonged to the 
41–50 age group. Although no statistically significant dif-
ference was found in the age distributions between our study 
and that of Simpson and Johnston [4], the female-manifest 
HD has significantly increased since 1984 (p = 0.0003) 
(Fig. 3b).
General practice (GP) coding
In GP referral letters for 56 symptomatic HD patients, 80.4% 
included the code “Huntington’s Chorea”, 3.6% as “Demen-
tia in Huntington’s disease”, and 16% had no HD code. Of 
the GP referral letters for 21 IPGEC, only 14.3% were cor-
rectly coded as "Genetic Disorder Carrier”, whilst 4.7% were 
coded as “Family History of Huntington’s Chorea.” Moreo-
ver, 42.9% were incorrectly coded as affected with “Hun-
tington’s Chorea”, and 38.1% had no HD code at all (Fig. 4).
Discussion
Here, we describe the rise in the estimates of the prevalence 
of manifest and IPGEC HD in the North of Scotland in over 
three decades, based upon data for a whole population. The 
strengths of this study were that it was population-based, 
with direct molecular confirmation and case note review in 
each case, ensuring that only truly symptomatic molecularly 
confirmed cases were included. Access to genetic labora-
tory records and referral processes, with a single HD clinic 
for the region, and embedded links with the family associa-
tion community-based nurse mean that ascertainment was 
maximised, and the opportunity to compare with a similarly 
conducted historic series adds value. An inevitable limita-
tion of such study is that patients tested out with the region 
who do not attend the local clinic would not be included.
The molecularly verified prevalence of motor-manifest 
HD in the North of Scotland in 2020 was 14.6 (95% CI 
14.3–15.3) per 100,000 manifest individuals, and 8.3 (95% 
CI 7.8–9.2) per 100,000 IPGEC were known to services. 
More women were identified with manifest HD than men, 
particularly in the 51–60 age group. Our prevalence rate is 
similar to the rate of 13.7 per 100,000 people in Caucasians, 
reported in British Columbia using similar methods [13].
The prevalence we have observed in the North of Scot-
land is almost three times greater than reported elsewhere 
in Europe, North America, and Australia (5.70 per 100,000 
people), and more than five times the estimated worldwide 
Fig. 1  a Prevalence of manifest and IPGEC HD in the North of 
Scotland b Bar charts, depicting the HD prevalence amongst health 
boards between 2016 and 2020
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prevalence of 2.71 per 100,000 people [14–16]. The widely 
quoted UK General Practice Research Database (UKGPRD) 
study estimated UK HD prevalence by examining diagnostic 
coding in routine clinical records of patients aged 20 and 
above from 625 of 9800 UK general practices. That study 
reported a prevalence of 12.3 per 100,000 people over 20 for 
the UK overall, and 16.1 per 100,000 estimated for Scotland, 
and only examined 186,902 records in Scotland, compared 
with the entire North of Scotland population of 870,520 peo-
ple in this study. In the Scottish census of 2011, 11,184,879 
of the population of 5,295,403 were aged 20 and under [11]. 
Thus, a prevalence of 16.1 per 100,000 in those over 20, only 
represents an all-age HD prevalence of the order of 12.4 per 
100,000 for Scotland, leaving the North of Scotland preva-
lence of 14.6 per 100,000 as amongst the highest in the UK.
Whilst the population in the North of Scotland decreased 
by 0.05% between 2016 and 2020, the number of mani-
fest patients increased by 7.4%, and the number of IPGEC 
increased by 23.3%. It is unlikely that the increase in 
reported prevalence is due a true increase, it is most likely 
due to a combination of better ascertainment, and increased 
longevity in the general population leading to more HD 
gene expansion carriers, surviving long enough to mani-
fest disease. It should be worth noting that in the interim 
between the two prevalence dates, there have been signifi-
cant advances in the pursuit of disease-modifying trials in 
Fig. 2  a Comparison of CAG 
repeats in Highland and Gram-
pian populations (manifest and 
IPGEC HD) on 01/01/2020 b 
Pattern of distribution of CAG 
numbers between NHS Gram-
pian and Highland HD, paired t 
test p value: 0.0125 (*)
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HD that may have had an impact in the number of people 
coming forward for testing and/or treatment to have access 
to these trials [17]. In our practice, we see more individuals 
seeking earlier diagnosis to benefit from medical and state-
funded financial support and care. Moreover, availability of 
direct mutation testing to identify the disorder in individuals 
with no known family history of HD, and increased aware-
ness of the condition in the medical profession and amongst 
the general public may also be contributing factors. The 
gender effects are likely to be in part be explained by dif-
ferences in life expectancy. All of the cases of manifest HD 
reported between the two prevalence dates were known to 
the clinic as IPGEC. Hence, at least part of the explanation 
for the increase in the prevalence could be that we diagnosis 
is now made earlier rather than those with HD living longer.
CAG repeat tracts were longer in cases from Highland 
than those from Grampian. Historically, these regions had 
discrete population origins, with Celts from Ireland migrat-
ing to replace the Pictish people across Highland but not 
the east of Grampian some 2000 years ago, and subsequent 
Viking influence in coastal regions, especially the North-
ern and Western Isles. More recently, following the early 
eighteenth century Jacobite wars of independence, major 
population movements were associated with clearances of 
land for sheep farming. Forced population movement to 
marginal coastal lands established the workforce for a her-
ring fishing industry around the Black Isle and the Gram-
pian coastline, with little inward migration until recently. 
In 1962, Lyon described a cluster of Grampian HD cases, 
whose origins trace back to the same Highland village [18]. 
Simpson [19] noted that there may be a founder effect within 
Grampian and proposed that the condition spread from the 
Black Isle to other coastal communities with the fishing 
industry. However, the decline in the fishing industry, the 
increase in young people seeking higher education, and 
the new opportunities for work with the oil industry and in 
the urban conurbations of Inverness and Aberdeen, appear 
to have mitigated this historic effect, and the cluster is no 
longer so prominent [20]. We propose that expansion of the 
CAG repeats in generations derived from the original Black 
Isle cluster CAG repeat tract has contributed to the pattern 
of larger repeats being seen in Highland.
It is likely that genetic background also contributes 
to the high HD prevalence. Kay et al. [21] reported that 
populations with high frequencies of intermediate alleles 
(27–35 CAG repeats)- such as Grampian at 3.7%- had high 
Fig. 3  a Gender distribution by age of manifest HD on 01/01/2020 in the North of Scotland. b Gender distribution by age of manifest HD on 
01/01/2020 and on 01/06/1984 in Grampian
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new HD mutation rates. There are three major haplogroups 
at the HD locus: A, B, and C, with A1 and A2 being the 
highest risk haplotypes. Warby et al. [22] identified that 
around 80% of the UK HD population examined had A1 
and A2 haplotypes, and that haplotype frequency varied 
in different populations around the world. Kay et al. [21] 
reported that, in North Scotland, 64% of HD alleles are 
A1, 9% A2a, and 18% A2b. The authors hypothesised that 
the proportion of the A1 allele in a population correlates 
with the new HD mutation frequency, and this may explain 
the high prevalence in Northern Scotland, and the UK.
In an autosomal dominant disorder, an equal number of 
men and women with manifest disease are expected. We, 
like Simpson and Johnston [4], found manifest females 
over-represented in the HD population (60.5%). As in most 
populations, female life expectancy exceeds that of males 
in the North of Scotland [11]. Although this sex difference 
in longevity contributes to the observed sex difference in 
manifest HD, the difference is too great for this to be the sole 
explanation of this female bias. It is generally thought that 
women are more likely to seek help and receive healthcare 
than men [23], but Simpson [19] noted that this is unlikely to 
be the full explanation, as there was no significant difference 
between male and female hospital admissions in the region.
Our data suggest that GP diagnostic codes under-repre-
sent symptomatic HD patients by 16%, but this is in part 
compensated for by an over-representation of IPGEC in the 
symptomatic cohort. Indeed, 43% of IPGEC that were coded 
as if their disease was manifest added 2.88 per 100,000 peo-
ple to the prevalence. In the symptomatic group, 16% were 
not coded as if they were manifest, and this would have 
underestimated the prevalence by 2.29 per 100,000 people. 
Overall, our data suggest that the estimates in the data link-
age paper [7] underestimated prevalence by around 2.2 per 
100,000 people. We propose that other regions could use this 
correction factor to inform service planning.
The demand for predictive testing may rise further if there 
is disease-modifying treatment becomes available or even 
before disease onset. Indeed, we have noticed an increase of 
predictive testing in the north of Scotland, as over half of the 
symptomatic HD have had a predictive test.
Conclusion
The prevalence of symptomatic HD in the North of Scotland 
has increased over the last 36 years from 9.94 per 100,000 to 
14.6 per 100,000 in total, 23.3 per 100,000 people are known 
to have a pathogenic HD mutation. This prevalence remains 
Fig. 4  GP Coding of symptomatic and IPGEC HD in NHS Grampian
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amongst the highest recorded. Prevalence can vary between 
adjoining health board areas, which could have major drug 
cost and service delivery implications, if expensive, com-
plexly administered, and effective therapies become availa-
ble. Nevertheless, the rise in reported prevalence in Northern 
Scotland is much less than recorded elsewhere, suggesting 
that variation in ascertainment may account for much more 
of the reported differences in prevalence worldwide than 
currently assumed. The marked recent rise in ascertain-
ment of identified pre-symptomatic gene expansion carriers 
reflects interest in treatment research and it is likely these 
numbers would increase much further, should an effective 
pre-symptomatic treatment become available.
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